About
With the federal government encouraging the states to develop their own diverse
set of False Claims Acts, your client faces a whole new layer of compliance
and enforcement. What's more, the practical impact of Medicare Part D
is still unclear, as companies wrestle with the potential fraud and abuse consequences.
Training and monitoring of sales reps continues to be a tricky issue, and the
government is looking even more closely now at the fraud and abuse implications
of educational programs.
With all these new challenges heaped on top of those that you've been
facing for years, as well as the significant criminal and civil penalties affiliated
with noncompliance, it is no wonder that federal, state, and global compliance
remains a major unresolved issue. The risks are too great to rest on your laurels – penalties
can cost a company hundreds of millions of dollars, and enforcement actions
can open the door to further risk of civil suits.
You need new and evolving strategies to stay ahead of the rapidly developing
trends. The publication for American Conference Institute's Sixth National Forum
on Fraud and Abuse in the Sales and Marketing of Drugs is a selection of presentations from industry experts that will provide you with the
practical guidance that was presented at the conference. In-house counsel, training managers and compliance officers from companies
such as Pfizer, FTI Consulting, Barr Laboratories,
Bayer HealthCare, Sanofi Aventis, Medical Marketing Solutions LLC and Pacific Pulmonary
Services provide frontline insights on creating and maintaining effective
compliance policies and what steps you can take to minimize your company's
exposure.
About
With the federal government encouraging the states to develop their own diverse
set of False Claims Acts, your client faces a whole new layer of compliance
and enforcement. What's more, the practical impact of Medicare Part D
is still unclear, as companies wrestle with the potential fraud and abuse consequences.
Training and monitoring of sales reps continues to be a tricky issue, and the
government is looking even more closely now at the fraud and abuse implications
of educational programs.
With all these new challenges heaped on top of those that you've been
facing for years, as well as the significant criminal and civil penalties affiliated
with noncompliance, it is no wonder that federal, state, and global compliance
remains a major unresolved issue. The risks are too great to rest on your laurels – penalties
can cost a company hundreds of millions of dollars, and enforcement actions
can open the door to further risk of civil suits.
You need new and evolving strategies to stay ahead of the rapidly developing
trends. The publication for American Conference Institute's Sixth National Forum
on Fraud and Abuse in the Sales and Marketing of Drugs is a selection of presentations from industry experts that will provide you with the
practical guidance that was presented at the conference. In-house counsel, training managers and compliance officers from companies
such as Pfizer, FTI Consulting, Barr Laboratories,
Bayer HealthCare, Sanofi Aventis, Medical Marketing Solutions LLC and Pacific Pulmonary
Services provide frontline insights on creating and maintaining effective
compliance policies and what steps you can take to minimize your company's
exposure.
Contents & Contributors
NAVIGATING THE NEW STATE FALSE CLAIMS LANDSCAPE
Adam B. Siegel, Covington & Burling LLP
NAVIGATING THE NEW STATE FALSE CLAIMS LANDSCAPE
T. Reed Stephens, Sonnenschein Nath & Rosenthal LLP
DEVELOPING PREEMPTION ARGUMENTS: ARE YOU SAFE FROM STATE LAW CLAIMS?
Lana Varney, Fulbright & Jaworski L.L.P.
PLANNING FOR A RISE IN FEDERAL AND STATE QUI TAM LITIGATION & INCREASED WHISTLEBLOWER ACTIVITY
Jonathan Diesenhaus, Hogan & Hartson LLP
Michael C. Theis, Hogan & Hartson LLP
WHAT EVERY FRAUD AND ABUSE LAWYER MUST KNOW ABOUT BILLING AND COLLECTION
Larri Short, Arent Fox LLP
ANTICIPATING AND PREVENTING FRAUD & ABUSE ACTIONS BASED ON MEDICARE PART D
Kathleen H. McGuan, Centers for Medicare and Medicaid Services (CMS)
Robert J. Hill, Reed Smith LLP
LESSONS LEARNED FROM RECENT SETTLEMENT AGREEMENTS AND DECISIONS RE: SALE AND MARKETING OF DRUGS
Elizabeth I. Hack, Sonnenschein Nath & Rosenthal LLP
LESSONS LEARNED FROM RECENT SETTLEMENT AGREEMENTS AND DECISIONS RE: SALE AND MARKETING OF DRUGS
Ken Barker, FTI Consulting
EDUCATIONAL & RESEARCH ACTIVITIES: AVOIDING ALLEGATIONS OF KICKBACKS AND OFF-LABEL PROMOTION
Carolyn J. McElroy, Pacific Pulmonary Services
Michael L. Koon, Shook, Hardy & Bacon L.L.P.
SALES & MARKETING COMPLIANCE: FRAUD & ABUSE
William J. Van Nostrand, Medical Marketing Solutions, LLC
FOSTERING AND MONITORING COMPLIANCE BY FIELD-BASED SALES REPS
Donald O. Beers, Arnold & Porter LLP
RETAINING CUSTOMERS AS CONSULTANTS, SPEAKERS AND FAIR MARKET VALUATION, ETC.
Thomas D. Forrester, Sanofi-Aventis
DIRECTING NON-U.S. BASED OPERATIONS ON GLOBAL FRAUD & ABUSE RISKS
Gary Giampetruzzi, Pfizer
ETHICAL ISSUES/LEGAL CONSTRAINTS IN INVESTIGATIONS
John C. Dodds, Morgan, Lewis & Bockius LLP
MAKING DISCLOSURES: PRESERVING AND PROTECTING ATTORNEY-CLIENT INFORMATION WHEN OPERATING A COMPLIANCE DEPARTMENT
Robert S. Salcido, Akin Gump Strauss Hauer & Feld LLP
DEVELOPING A STATE-LAW COMPLIANCE PROGRAM UNDER THE DEFICIT REDUCTION ACT OF 2005
Trudy Seeley, Sanofi Aventis
Publication Details